Who is sponsoring NCT04563689?

NCT04563689 is sponsored by Dentaid SL.

What drugs are being tested in NCT04563689?

Interventions in NCT04563689: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control), placebo rinse.

Is NCT04563689 still recruiting?

NCT04563689 is currently completed. Last updated 20 November 2020.

Last reviewed 2020-11-20 · How we verify

NCT04563689

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients

Completed NA Last updated 20 November 2020

What this trial tests

NA trial testing CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) in Covid19 in 23 participants. Completed in 23 October 2020.

Timeline

18 June 2020

Primary endpoint
22 October 2020

23 October 2020

Quick facts

Lead sponsor	Dentaid SL
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	23
Start date	18 June 2020
Primary completion	22 October 2020
Estimated completion	23 October 2020
Sites	1 location across Colombia

Drugs / interventions tested

CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)
placebo rinse — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Dentaid SL — full company profile →

Who can join

Adults 18 to 90, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, double-blind, placebo-controlled pilot study to evalaute viral load in saliva of COVID19+ patients using quantitative PCR, before and after use of active or placebo rinses

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Review of the use of nasal and oral antiseptics during a global pandemic.
Stathis C, Victoria N, Loomis K, Nguyen SA, et al · · 2021 · cited 21× · PMID 33464122 · DOI 10.2217/fmb-2020-0286

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Dentaid SL trials

Trials by the same sponsor.

NCT06251089 — Effect of Cetylpyridinium Chloride (CPC) Rinse in Viral Upper Respiratory Tract Infections (vURTI) · NA · completed
NCT04757818 — Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19 · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04563689 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dentaid SL
Last refreshed: 20 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04563689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing